Glaxo Wellcome Inc. has received reports of prescription dispensing errors involving LAMICTAL (lamotrigine) Tablets and
LAMISIL (terbinafine hydrochloride) Tablets resulting in serious adverse events. The error reports involve dispensing Lamictal
Tablets when Lamisil Tablets were prescribed and the reverse scenario.
Patients with epilepsy who do not receive their antiepileptic drug LAMICTAL due to a dispensing error would be
inadequately treated and could experience serious consequences including status epilepticus. Conversely, patients erroneously
receiving Lamictal instead of their antifungal drug LAMISIL would be unnecessarily subjected to a risk of potential side
effects (including serious rash). This is especially true if patients receive an initial high dose of Lamictal
LAMICTAL is an antiepileptic drug marketed as 25-, 100-, 150-, and 200-mg six-sided, shield- shaped tablets bearing
"Lamictal" and the numeric representation of the strength (e.g., "Lamictal 150"). Lamictal Chewable Dispersible Tablets are
5-mg and 25-mg white tablets engraved with "GX CL2" and "GX CL5," respectively. To initiate therapy with Lamictal, the
dose is titrated over a period of several weeks.
LAMISIL is an antifungal drug marketed as 250-mg circular, biconvex, bevelled tablets bearing "Lamisil" on one side and
"250" on the other side. The recommended dosage for Lamisil is one 250-mg tablet daily for six or twelve weeks depending on
the affected nail. Topical formulations of Lamisil are also available by prescription and over-the-counter.
Pharmacists are asked to be alert for both written and oral prescriptions for LAMICTAL and LAMISIL, and to promptly share information with their staffs. Measures to avoid dispensing errors should be assessed and implemented as appropriate.
Pharmacists aware of a prescription dispensing error involving these products are asked to contact the appropriate manufacturer:
For further information on Lamictal, please call 1-888-TALK-2-GW (1-888-825-5249).